| pubmed-article:20199127 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20199127 | lifeskim:mentions | umls-concept:C0007102 | lld:lifeskim |
| pubmed-article:20199127 | lifeskim:mentions | umls-concept:C0071216 | lld:lifeskim |
| pubmed-article:20199127 | lifeskim:mentions | umls-concept:C0086860 | lld:lifeskim |
| pubmed-article:20199127 | lifeskim:mentions | umls-concept:C1515035 | lld:lifeskim |
| pubmed-article:20199127 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:20199127 | pubmed:dateCreated | 2010-3-4 | lld:pubmed |
| pubmed-article:20199127 | pubmed:abstractText | Colon cancer is the third and fourth most prevalent cancer among Iranian men and women, respectively. Suicide gene therapy is one of the alternative therapeutic modalities for cancer. The application of specific promoters for therapeutic genes should decrease the adverse effects of this modality. The combined aims of this study were to design a specific suicide gene therapy construct for colon cancer and study its effect in distinct representatives of transformed and nontransformed cells. The KRAS oncogene signaling pathway is one of the most important signaling pathways activated in colon cancer; therefore, we inserted the urokinase plasminogen activator receptor (uPAR; PLAUR gene) promoter as one of the upregulated promoters by this pathway upstream of a suicide gene (thymidine kinase [TK]) and a reporter gene (beta-galactosidase, beta-gal [LacZ]). This promoter is a natural combination of different motifs responsive to the RAS signaling pathway, such as the transcription factors AP1 (FOS/JUN), SP1, SP3, and AP2alpha, and nuclear factor kappa B (NFkappaB). The reporter plasmid under the control of the uPAR promoter (PUCUPARLacZ) had the ability to express beta-gal in colon cancer cells (human colon adenocarcinoma [SW480] and human colorectal carcinoma [HCT116] cell lines), while it could not express beta-gal in nontransformed human umbilical vein endothelial cells (HUVEC) and normal colon cells. After confirming the ability of pUCUPARTK (suicide plasmid) to express TK in SW480 and HCT116 cells by real-time PCR, cytotoxicity assays showed that pUCUPARTK decreased the viability of these cells in the presence of ganciclovir 20 and 40 microg/mL (and higher), respectively. Although M30 CytoDEATH antibody could not detect a significant rate of apoptosis induced by ganciclovir in pUCUPARTK-transfected HCT116 cells, the percentage of stained cells was marked in comparison with untreated cells. While this antibody could detect apoptosis in HCT116 cell line transfected with positive control plasmid, it could not detect apoptosis in SW480 cells transfected with the same positive control. This discrepancy could be attributed to the different mechanisms of TK/ganciclovir-induced apoptosis in tumor protein p53 (TP53)-expressing (HCT116) and -deficient (SW480) cells. Annexin-propidium iodide staining could detect apoptosis in treated, pUCUPARTK-transfected SW480 and HCT116 cells. This study showed that the uPAR promoter can be considered as a suitable candidate for specific suicide gene therapy of colon cancer and probably other cancers in which the RAS signaling pathway is involved in their carcinogenesis process. | lld:pubmed |
| pubmed-article:20199127 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20199127 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20199127 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20199127 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20199127 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20199127 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20199127 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20199127 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20199127 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:20199127 | pubmed:issn | 1173-8804 | lld:pubmed |
| pubmed-article:20199127 | pubmed:author | pubmed-author:ZeinaliSirous... | lld:pubmed |
| pubmed-article:20199127 | pubmed:author | pubmed-author:Teimoori-Tool... | lld:pubmed |
| pubmed-article:20199127 | pubmed:author | pubmed-author:AzadmaneshKay... | lld:pubmed |
| pubmed-article:20199127 | pubmed:author | pubmed-author:AmanzadehAmir... | lld:pubmed |
| pubmed-article:20199127 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:20199127 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:20199127 | pubmed:volume | 24 | lld:pubmed |
| pubmed-article:20199127 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20199127 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20199127 | pubmed:pagination | 131-46 | lld:pubmed |
| pubmed-article:20199127 | pubmed:meshHeading | pubmed-meshheading:20199127... | lld:pubmed |
| pubmed-article:20199127 | pubmed:meshHeading | pubmed-meshheading:20199127... | lld:pubmed |
| pubmed-article:20199127 | pubmed:meshHeading | pubmed-meshheading:20199127... | lld:pubmed |
| pubmed-article:20199127 | pubmed:meshHeading | pubmed-meshheading:20199127... | lld:pubmed |
| pubmed-article:20199127 | pubmed:meshHeading | pubmed-meshheading:20199127... | lld:pubmed |
| pubmed-article:20199127 | pubmed:meshHeading | pubmed-meshheading:20199127... | lld:pubmed |
| pubmed-article:20199127 | pubmed:meshHeading | pubmed-meshheading:20199127... | lld:pubmed |
| pubmed-article:20199127 | pubmed:meshHeading | pubmed-meshheading:20199127... | lld:pubmed |
| pubmed-article:20199127 | pubmed:meshHeading | pubmed-meshheading:20199127... | lld:pubmed |
| pubmed-article:20199127 | pubmed:meshHeading | pubmed-meshheading:20199127... | lld:pubmed |
| pubmed-article:20199127 | pubmed:meshHeading | pubmed-meshheading:20199127... | lld:pubmed |
| pubmed-article:20199127 | pubmed:meshHeading | pubmed-meshheading:20199127... | lld:pubmed |
| pubmed-article:20199127 | pubmed:meshHeading | pubmed-meshheading:20199127... | lld:pubmed |
| pubmed-article:20199127 | pubmed:meshHeading | pubmed-meshheading:20199127... | lld:pubmed |
| pubmed-article:20199127 | pubmed:meshHeading | pubmed-meshheading:20199127... | lld:pubmed |
| pubmed-article:20199127 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20199127 | pubmed:articleTitle | Selective suicide gene therapy of colon cancer exploiting the urokinase plasminogen activator receptor promoter. | lld:pubmed |
| pubmed-article:20199127 | pubmed:affiliation | Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran. | lld:pubmed |
| pubmed-article:20199127 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20199127 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
